Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Current Drug Discovery Technologies
Title: Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Volume: 6 Issue: 4
Author(s): Johann O. Schroder and Rainald A. Zeuner
Affiliation:
Keywords: Systemic lupus erythematosus, biologics, clinical trials
Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by specific organ manifestations and the production of autoantibodies to nuclear antigens. SLE can induce severe organ damage and carries the risk of fatal outcome. During recent years, no major progress has been made regarding new treatment options except for the introduction of mycophenolate mofetil. Therefore, the results of several large clinical trials using biological agents for treatment of SLE were hopefully awaited. Yet, the application of abatacept, belimumab and rituximab, respectively, to non-renal or renal lupus patients surprisingly has not been successful. Other studies using different agents have not been completed yet. Nevertheless, the results available so far will have a significant impact on the design of future clinical trials and will stimulate the debate on new targets for treatment of SLE.
Export Options
About this article
Cite this article as:
Schroder O. Johann and Zeuner A. Rainald, Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges, Current Drug Discovery Technologies 2009; 6 (4) . https://dx.doi.org/10.2174/157016309789869010
DOI https://dx.doi.org/10.2174/157016309789869010 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The TOLL-like / Type-I Interferon Pathways as Emerging Therapeutic Targets for Autoimmune Diseases
Drug Design Reviews - Online (Discontinued) Molecular Mechanism of the Affinity Interactions between BAFF and Its Peptides by Molecular Simulations
Protein & Peptide Letters ImmunemiR - A Database of Prioritized Immune miRNA Disease Associations and its Interactome
MicroRNA CTLA-4Ig: Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews The Cancer Hygiene Hypothesis: From Theory to Therapeutic Helminths
Current Cancer Therapy Reviews Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Genomic Strategies in Pharmacology of Asthma and Autoimmunity
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthetic Peptides for the Immunodiagnosis of Human Diseases
Current Medicinal Chemistry Juvenile Systemic Lupus Erythematosus
Current Pediatric Reviews Inhibitors of AP-1 and NF-κB Mediated Transcriptional Activation: Therapeutic Potential in Autoimmune Diseases and Structural Diversity
Current Medicinal Chemistry Natural Tregs in Systemic Lupus Erythematosus
Current Immunology Reviews (Discontinued) Editorial: (Thematic Issue: Autoimmune diseases: What have we learned from mice?)
Current Pharmaceutical Design Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Sex Steroids in Autoimmune Diseases
Current Topics in Medicinal Chemistry Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics Autoantibody-Induced Formation of Immune Complexes in Normal Human Serum
Current Pharmaceutical Design Risk Factors for Serious Adverse Effects of Thiopurines in Patients with Crohn’s Disease
Current Drug Safety Update on Intravenous Immunoglobulins (IVIg) Mechanisms of Action and Off- Label use in Autoimmune Diseases
Current Pharmaceutical Design